Pharmaceuticals, Biotechnology & Life Sciences

Northwest Biotherapeutics

Phio Pharmaceuticals, a biotech firm focused on cancer immunotherapy, showcased at 2026 DealFlow Discovery and faces volatile stock yet promising asset value.

First patient dose of Crescent Biopharma’s CR‑001 bispecific antibody is now in the ASCEND Phase 1/2 trial, a global study targeting advanced solid tumors and combining PD‑1 and VEGF blockade for safer, potentially more effective cancer treatment.

Spruce Biosciences, a Nasdaq‑listed biotech focused on endocrinology and orphan drugs, sees a boost from Harbour BioMet’s stake amid volatile stock swings.

KalVista Pharmaceuticals’ focus on protease inhibitors and its upcoming EKTERLY presentation signal promising biotech innovation amid market volatility.

Viatris’ UBS upgrade spotlights disciplined capital allocation, rising profitability, and a strategic pipeline poised to boost shareholder value.

QIAGEN NV gains from a bullish European market: strong fundamentals, expanding diagnostics portfolio, and a positive outlook amid industry consolidation.

Tonix Pharmaceuticals faces investor doubt as its stock plummets, lack of new milestones, and negative earnings raise concerns about future pain‑management prospects.

Photocure ASA tops Q4 2025 with strong Hexvix/Cysview growth, expanding U.S. blue‑light cystoscopy, and bullish 2026 revenue outlook.

Innate Pharma SA: a Marseille‑based biotech pioneer in antibody oncology, from IPH4102 to Lumoxiti, backed by AstraZeneca and MedImmune partnerships.